USFDA asks Philips Respironics to notify patients about ventilator recall

"Taking this action today enables the FDA to mandate that Philips Respironics improve its communication about the recall and the serious risk posed by the foam used in the recalled products with patients," the regulator added.

Published On 2022-03-12 04:47 GMT   |   Update On 2022-03-12 04:47 GMT
Advertisement

New Delhi: The U.S. Food and Drug Administration (FDA) asked Dutch medical equipment maker Philips Respironics on Thursday to notify patients about the company's recall of certain ventilators and other breathing assistance machines in June last year.

FDA said in a statement that it had determined the order necessary, citing the risk of harm posed by the recalled products.
"Taking this action today enables the FDA to mandate that Philips Respironics improve its communication about the recall and the serious risk posed by the foam used in the recalled products with patients," the regulator added.
The company said in a statement it would be working with its durable medical equipment (DME) customers to allow the company to directly contact those patients and other end-users that may not yet have received notice of the recall.
Philips Respironics had recalled some breathing devices and ventilators in June last year because of a foam part that might degrade and become toxic, potentially causing cancer.
The health regulator has also recommended the company to provide monthly updates to device users that include information on expected time for replacement and current rate of replacement of recalled devices.

Read Also - Philips expanded ventilator recall classified as most serious by USFDA

Philips invasive and noninvasive ventilators support the needs of the patient and care providers from hospital through the home. Our solutions are designed to deliver the highest possible clinical and patient experience. The final goal of our partnership is to help care providers and health systems as they navigate complex and changing patient conditions and care settings when treating respiratory insufficiency.

Read Also - Philips, USFDA in talks post new ventilator findings


Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News